Company Presentation

CanVirex is a privately-owned, Swiss immuno-viro-therapeutics company with headquarters in Basel. The company develops a versatile platform for novel cancer therapies based on oncolytic viruses. CanVirex is ready for the clinical translation of its proprietary cutting-edge platform technology with the potential to become a game changer in immuno-oncology. The pre-clinical development of our lead candidate is completed and manufacturing of Clinical Trial Material is underway.